Our project partner 4DCell, a biotechnology company located in Paris that aims to revolutionize cell culture, was among 26 European startups invited to attend the EIC Multi-Corporate Day held by the European Innovation Council (EIC) in Brussels, Belgium from 8-9 October 2025. The event attracted representatives from major corporations and offered an excellent opportunity to connect with these world leaders in the pharmaceutical and consumer goods sectors eager to explore advancements in biotechnology, artificial intelligence, and industrial solutions. The structured format featured expert coaching, targeted pitches, and one-on-one meetings with corporate stakeholders, which allowed effective exploration of potential pilots and co-development projects.

At the event, 4DCell presented its innovative SmartHeart cardiac testing platform directly to decision-makers from companies such as Procter & Gamble, Air Liquide, Chiesi Group, and Nestlé, all companies that are actively seeking these kind of innovations. The SmartHeart design is an easy-to-use 3D in vitro heart model that requires a minimal number of cells and faithfully reproduces in vivo physiology, enabling precise efficacy and cardiotoxicity measurements. It is suitable for testing new compounds, assessing the toxicity of drugs targeting various pathologies, and for easy scaling to meet high-throughput screening requirements.

The EIC Multi-Corporate Day did not only open new doors for collaboration and innovation, but was also a significant step forward for 4Dcell whose focus remains on advancing biotechnology and human-relevant models. They are committed to becoming the leading provider of advanced, ethical, and reproducible in vitro models with the goal is to help biomedical researchers accelerate drug discovery and toxicology studies while significantly reducing reliance on animal testing.